Psoriasis

The National Psoriasis Foundation dedicated August to psoriasis education, awareness and education, designating it Psoriasis Action Month.

In September 2022, the FDA approved deucravacitinib for moderate-to-severe plaque psoriasis, officially introducing tyrosine kinase 2 inhibition to clinics across the United States.

In patients with early and complete clearance of psoriasis, extending the guselkumab dosing interval to every 16 weeks maintained disease control as well as an 8-week interval, according to a study published in JAMA Dermatology.

Patients and clinicians agree that as-needed use of biologic therapy has benefits over continuous long-term biologic use for the treatment of psoriasis, according to a study.